name,source,assaytype,SHAP,description,value,pred,influence,smiles,SHAP contribution to Toxicity,compound
7,Preclinical hepatotoxicity,Animal hepatotoxicity,0.03251576627300221,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.9410447669779352,True,,CCCCOCCO,Positive,2-Butoxyethanol
11,Diverse DILI C,Heterogenous Data ,0.00516971113886361,"Transient liver function abnormalities, adverse hepatic effects",0.61208742420217,True,,CCCCOCCO,Positive,2-Butoxyethanol
2,Liver Toxicity Knowledge Base,DILI,-0.026407810581778903,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.33242533844223165,False,,CCCCOCCO,Negative,2-Butoxyethanol
3,Human hepatotoxicity,Human hepatotoxicity,-0.025325118853484804,"Human hepatotoxicity, hepatobiallry",0.2084942050187302,False,,CCCCOCCO,Negative,2-Butoxyethanol
5,Animal hepatotoxicity A,Animal hepatotoxicity,-0.0008088894232236655,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.2900026134591961,False,,CCCCOCCO,Negative,2-Butoxyethanol
6,Animal hepatotoxicity B,Animal hepatotoxicity,-0.0057700461489013375,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.20095983428419945,False,,CCCCOCCO,Negative,2-Butoxyethanol
8,Diverse DILI A,Heterogenous Data ,-0.0006729850363475804,Large-scale and diverse ddrug induced liver injury dataset,0.49663180015070935,False,,CCCCOCCO,Negative,2-Butoxyethanol
10,Diverse DILI B,Heterogenous Data ,-0.009957287257757338,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.16935956273361433,False,,CCCCOCCO,Negative,2-Butoxyethanol
14,BESP,Mechanisms of Liver Toxicity,-0.006260867449336517,BESP Bile Salt Export Pump Inhibition,0.18385826844126518,False,,CCCCOCCO,Negative,2-Butoxyethanol
15,Mitotox,Mechanisms of Liver Toxicity,-0.009220326248271491,Mitotox ,5.857740585774059e-05,False,,CCCCOCCO,Negative,2-Butoxyethanol
16,Reactive Metabolite,Mechanisms of Liver Toxicity,-0.0027646319695263048,Reactive Metabolite Formation,0.526412938236733,True,,CCCCOCCO,Negative,2-Butoxyethanol
2,Liver Toxicity Knowledge Base,DILI,0.00020377598507224318,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.6600972918775736,True,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,Positive,Acitretin
6,Animal hepatotoxicity B,Animal hepatotoxicity,0.002695546188847817,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.5645976554487601,True,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,Positive,Acitretin
7,Preclinical hepatotoxicity,Animal hepatotoxicity,0.03095476465914657,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.8347595437253803,True,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,Positive,Acitretin
14,BESP,Mechanisms of Liver Toxicity,0.010781894792429825,BESP Bile Salt Export Pump Inhibition,0.8125935368931662,True,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,Positive,Acitretin
15,Mitotox,Mechanisms of Liver Toxicity,0.011461751721048123,Mitotox ,0.16180908103770528,False,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,Positive,Acitretin
16,Reactive Metabolite,Mechanisms of Liver Toxicity,0.00034888214542236524,Reactive Metabolite Formation,0.1965254549389991,False,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,Positive,Acitretin
3,Human hepatotoxicity,Human hepatotoxicity,-0.0028416589128227583,"Human hepatotoxicity, hepatobiallry",0.5304795963270551,True,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,Negative,Acitretin
5,Animal hepatotoxicity A,Animal hepatotoxicity,-0.0009899098752498686,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.2531554081536377,False,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,Negative,Acitretin
8,Diverse DILI A,Heterogenous Data ,-0.0021653698871446155,Large-scale and diverse ddrug induced liver injury dataset,0.3578777897443128,False,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,Negative,Acitretin
10,Diverse DILI B,Heterogenous Data ,-0.005845080876121511,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.25598637291776954,False,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,Negative,Acitretin
11,Diverse DILI C,Heterogenous Data ,-0.001817341968114167,"Transient liver function abnormalities, adverse hepatic effects",0.358043656272269,False,,COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,Negative,Acitretin
6,Animal hepatotoxicity B,Animal hepatotoxicity,0.0017112925443309361,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.554113113322599,True,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1=O,Positive,Astaxanthin
14,BESP,Mechanisms of Liver Toxicity,0.008585487034366483,BESP Bile Salt Export Pump Inhibition,0.7554452583285571,True,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1=O,Positive,Astaxanthin
15,Mitotox,Mechanisms of Liver Toxicity,0.006793593980760974,Mitotox ,0.1858010106364787,False,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1=O,Positive,Astaxanthin
2,Liver Toxicity Knowledge Base,DILI,-0.006173314880668899,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.5142560498342333,True,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1=O,Negative,Astaxanthin
3,Human hepatotoxicity,Human hepatotoxicity,-0.014894029828274282,"Human hepatotoxicity, hepatobiallry",0.2656422870826537,False,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1=O,Negative,Astaxanthin
5,Animal hepatotoxicity A,Animal hepatotoxicity,-0.00192418720394187,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.1623325622396331,False,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1=O,Negative,Astaxanthin
7,Preclinical hepatotoxicity,Animal hepatotoxicity,-0.010612821257590294,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.6840109560122741,True,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1=O,Negative,Astaxanthin
8,Diverse DILI A,Heterogenous Data ,-0.006919827540663632,Large-scale and diverse ddrug induced liver injury dataset,0.12565915647655768,False,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1=O,Negative,Astaxanthin
10,Diverse DILI B,Heterogenous Data ,-0.0048711816323749515,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.5050148081628648,True,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1=O,Negative,Astaxanthin
11,Diverse DILI C,Heterogenous Data ,-0.006034262300445004,"Transient liver function abnormalities, adverse hepatic effects",0.29659154678796107,False,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1=O,Negative,Astaxanthin
16,Reactive Metabolite,Mechanisms of Liver Toxicity,-0.0001630642900086173,Reactive Metabolite Formation,0.20773570076932865,False,,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C2=C(C)C(=O)[C@@H](O)CC2(C)C)C(C)(C)C[C@H](O)C1=O,Negative,Astaxanthin
2,Liver Toxicity Knowledge Base,DILI,0.0017993355971780871,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.6252319253086431,True,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,Positive,Cabazitaxel
6,Animal hepatotoxicity B,Animal hepatotoxicity,7.247625096520859e-05,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.10706487714080716,False,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,Positive,Cabazitaxel
8,Diverse DILI A,Heterogenous Data ,0.0018764335216073932,Large-scale and diverse ddrug induced liver injury dataset,0.4525355317898259,False,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,Positive,Cabazitaxel
10,Diverse DILI B,Heterogenous Data ,0.026499304651639848,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.7879761780102033,True,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,Positive,Cabazitaxel
11,Diverse DILI C,Heterogenous Data ,0.0020896486575685833,"Transient liver function abnormalities, adverse hepatic effects",0.4160621023258817,False,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,Positive,Cabazitaxel
14,BESP,Mechanisms of Liver Toxicity,0.007864774466268026,BESP Bile Salt Export Pump Inhibition,0.8074656701895807,True,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,Positive,Cabazitaxel
15,Mitotox,Mechanisms of Liver Toxicity,0.009961373231135606,Mitotox ,0.4878256787309286,False,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,Positive,Cabazitaxel
16,Reactive Metabolite,Mechanisms of Liver Toxicity,0.0027203988016408147,Reactive Metabolite Formation,0.05579709730933863,False,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,Positive,Cabazitaxel
3,Human hepatotoxicity,Human hepatotoxicity,-5.146557053861095e-05,"Human hepatotoxicity, hepatobiallry",0.4483324011925015,False,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,Negative,Cabazitaxel
5,Animal hepatotoxicity A,Animal hepatotoxicity,-0.0006005156854053738,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.13247208093482135,False,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,Negative,Cabazitaxel
7,Preclinical hepatotoxicity,Animal hepatotoxicity,-0.0014447657338217516,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.7133576432096586,True,,CO[C@H]1C(=O)[C@]2(C)[C@@H](OC)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C,Negative,Cabazitaxel
2,Liver Toxicity Knowledge Base,DILI,0.01913403772870065,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.8803704381690581,True,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Positive,Clopidogrel
3,Human hepatotoxicity,Human hepatotoxicity,0.006423523096541737,"Human hepatotoxicity, hepatobiallry",0.850752789862853,True,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Positive,Clopidogrel
5,Animal hepatotoxicity A,Animal hepatotoxicity,0.0022288145151359872,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.8337013277159886,True,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Positive,Clopidogrel
6,Animal hepatotoxicity B,Animal hepatotoxicity,0.0037168026879125108,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.6640097225817579,True,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Positive,Clopidogrel
7,Preclinical hepatotoxicity,Animal hepatotoxicity,0.02005456236762901,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.8343313297791751,True,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Positive,Clopidogrel
8,Diverse DILI A,Heterogenous Data ,0.005619209812595901,Large-scale and diverse ddrug induced liver injury dataset,0.5754535508007428,True,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Positive,Clopidogrel
11,Diverse DILI C,Heterogenous Data ,0.005132984659668255,"Transient liver function abnormalities, adverse hepatic effects",0.550978739474539,True,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Positive,Clopidogrel
14,BESP,Mechanisms of Liver Toxicity,0.0033349014379476303,BESP Bile Salt Export Pump Inhibition,0.9287085388226421,True,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Positive,Clopidogrel
15,Mitotox,Mechanisms of Liver Toxicity,0.0030174909942765364,Mitotox ,0.09187430224596237,False,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Positive,Clopidogrel
16,Reactive Metabolite,Mechanisms of Liver Toxicity,0.00048027275121221343,Reactive Metabolite Formation,0.2031595594459427,False,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Positive,Clopidogrel
10,Diverse DILI B,Heterogenous Data ,-0.00893651753062214,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.30061135087280283,False,,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,Negative,Clopidogrel
2,Liver Toxicity Knowledge Base,DILI,0.001526296614426172,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.6108440589632238,True,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,Positive,Docetaxel
8,Diverse DILI A,Heterogenous Data ,0.0026282246513672667,Large-scale and diverse ddrug induced liver injury dataset,0.4616065660399637,False,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,Positive,Docetaxel
10,Diverse DILI B,Heterogenous Data ,0.024874740761387956,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.8017212158921005,True,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,Positive,Docetaxel
11,Diverse DILI C,Heterogenous Data ,0.0021209128048178634,"Transient liver function abnormalities, adverse hepatic effects",0.44967388889924925,False,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,Positive,Docetaxel
14,BESP,Mechanisms of Liver Toxicity,0.008571169049500898,BESP Bile Salt Export Pump Inhibition,0.9019979737923204,True,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,Positive,Docetaxel
15,Mitotox,Mechanisms of Liver Toxicity,0.01036164493621192,Mitotox ,0.4251355761406876,False,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,Positive,Docetaxel
16,Reactive Metabolite,Mechanisms of Liver Toxicity,0.0036237441290672755,Reactive Metabolite Formation,0.04424950744541947,False,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,Positive,Docetaxel
3,Human hepatotoxicity,Human hepatotoxicity,-4.723191150617323e-05,"Human hepatotoxicity, hepatobiallry",0.4367921778042746,False,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,Negative,Docetaxel
5,Animal hepatotoxicity A,Animal hepatotoxicity,-0.0006716124902552343,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.13085577998403275,False,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,Negative,Docetaxel
6,Animal hepatotoxicity B,Animal hepatotoxicity,-0.00012674264405489893,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.11051852240367295,False,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,Negative,Docetaxel
7,Preclinical hepatotoxicity,Animal hepatotoxicity,-0.0021040682912326406,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.6933987645481231,True,,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@H]21)C3(C)C,Negative,Docetaxel
2,Liver Toxicity Knowledge Base,DILI,0.01683403764267737,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.832060259962281,True,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Positive,Doxycycline
3,Human hepatotoxicity,Human hepatotoxicity,0.007249307814275815,"Human hepatotoxicity, hepatobiallry",0.800172534312753,True,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Positive,Doxycycline
8,Diverse DILI A,Heterogenous Data ,0.008961638300839308,Large-scale and diverse ddrug induced liver injury dataset,0.8143397967318246,True,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Positive,Doxycycline
10,Diverse DILI B,Heterogenous Data ,0.015063834597573987,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.8612144978904321,True,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Positive,Doxycycline
11,Diverse DILI C,Heterogenous Data ,0.006538665692525082,"Transient liver function abnormalities, adverse hepatic effects",0.6938043337320092,True,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Positive,Doxycycline
15,Mitotox,Mechanisms of Liver Toxicity,0.002626054829276351,Mitotox ,0.11800912575370122,False,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Positive,Doxycycline
5,Animal hepatotoxicity A,Animal hepatotoxicity,-0.0023987497728200206,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.07151820432229467,False,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Negative,Doxycycline
6,Animal hepatotoxicity B,Animal hepatotoxicity,-0.00286508937912304,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.136605526394871,False,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Negative,Doxycycline
7,Preclinical hepatotoxicity,Animal hepatotoxicity,-0.011533299180277908,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.6450583643430565,True,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Negative,Doxycycline
14,BESP,Mechanisms of Liver Toxicity,-0.004516674823212365,BESP Bile Salt Export Pump Inhibition,0.011059931373982304,False,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Negative,Doxycycline
16,Reactive Metabolite,Mechanisms of Liver Toxicity,-3.955358992428918e-05,Reactive Metabolite Formation,0.11494133705917134,False,,C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,Negative,Doxycycline
2,Liver Toxicity Knowledge Base,DILI,0.014002839541161296,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.8722233782782582,True,,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,Positive,Entacapone
3,Human hepatotoxicity,Human hepatotoxicity,0.005915358564468965,"Human hepatotoxicity, hepatobiallry",0.6653782002196121,True,,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,Positive,Entacapone
5,Animal hepatotoxicity A,Animal hepatotoxicity,0.00011191116366223895,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.29353601048714556,False,,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,Positive,Entacapone
6,Animal hepatotoxicity B,Animal hepatotoxicity,0.0044621134562995044,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.44034809274536724,False,,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,Positive,Entacapone
7,Preclinical hepatotoxicity,Animal hepatotoxicity,0.01535606373611299,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.7500042003838076,True,,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,Positive,Entacapone
10,Diverse DILI B,Heterogenous Data ,0.008409015851082781,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.5721560448168228,True,,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,Positive,Entacapone
11,Diverse DILI C,Heterogenous Data ,0.004622874693270354,"Transient liver function abnormalities, adverse hepatic effects",0.6141480758629283,True,,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,Positive,Entacapone
14,BESP,Mechanisms of Liver Toxicity,0.0029442193363293074,BESP Bile Salt Export Pump Inhibition,0.7471938963715417,True,,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,Positive,Entacapone
15,Mitotox,Mechanisms of Liver Toxicity,0.006466651621928113,Mitotox ,0.20343119860930867,False,,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,Positive,Entacapone
8,Diverse DILI A,Heterogenous Data ,-0.0010236576326831178,Large-scale and diverse ddrug induced liver injury dataset,0.5346057891555103,True,,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,Negative,Entacapone
16,Reactive Metabolite,Mechanisms of Liver Toxicity,-0.00020860411353058195,Reactive Metabolite Formation,0.07877072061780173,False,,CCN(CC)C(=O)/C(C#N)=C/c1cc(O)c(O)c([N+](=O)[O-])c1,Negative,Entacapone
2,Liver Toxicity Knowledge Base,DILI,0.01548419443526698,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.8585312709736342,True,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,Positive,Enzalutamide
3,Human hepatotoxicity,Human hepatotoxicity,0.007279350348059748,"Human hepatotoxicity, hepatobiallry",0.9048448483030989,True,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,Positive,Enzalutamide
5,Animal hepatotoxicity A,Animal hepatotoxicity,6.802209809962388e-05,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.3084975716110533,False,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,Positive,Enzalutamide
6,Animal hepatotoxicity B,Animal hepatotoxicity,0.003411803363096339,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.5182040785920313,True,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,Positive,Enzalutamide
7,Preclinical hepatotoxicity,Animal hepatotoxicity,0.022268035276248755,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.9038293507039696,True,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,Positive,Enzalutamide
8,Diverse DILI A,Heterogenous Data ,0.0066981441434441095,Large-scale and diverse ddrug induced liver injury dataset,0.6319465908096557,True,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,Positive,Enzalutamide
10,Diverse DILI B,Heterogenous Data ,0.012677849681587574,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.7473267515080732,True,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,Positive,Enzalutamide
11,Diverse DILI C,Heterogenous Data ,0.006628923100251643,"Transient liver function abnormalities, adverse hepatic effects",0.6300012978089139,True,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,Positive,Enzalutamide
14,BESP,Mechanisms of Liver Toxicity,0.0029172699388913185,BESP Bile Salt Export Pump Inhibition,0.7997498465160945,True,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,Positive,Enzalutamide
15,Mitotox,Mechanisms of Liver Toxicity,0.006743041934627254,Mitotox ,0.5222145181657307,True,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,Positive,Enzalutamide
16,Reactive Metabolite,Mechanisms of Liver Toxicity,-0.0009070232244844194,Reactive Metabolite Formation,0.23513569903654846,False,,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,Negative,Enzalutamide
2,Liver Toxicity Knowledge Base,DILI,0.0162611481758459,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.9227615826599846,True,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Positive,Gemcitabine
3,Human hepatotoxicity,Human hepatotoxicity,0.006676989425128535,"Human hepatotoxicity, hepatobiallry",0.9170690701533202,True,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Positive,Gemcitabine
5,Animal hepatotoxicity A,Animal hepatotoxicity,0.0007134735553958538,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.35947021539999774,False,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Positive,Gemcitabine
8,Diverse DILI A,Heterogenous Data ,0.012539206445297754,Large-scale and diverse ddrug induced liver injury dataset,0.6167438756398345,True,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Positive,Gemcitabine
10,Diverse DILI B,Heterogenous Data ,0.008200800672050276,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.5525249352703664,True,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Positive,Gemcitabine
11,Diverse DILI C,Heterogenous Data ,0.006911349998213095,"Transient liver function abnormalities, adverse hepatic effects",0.6204412534362419,True,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Positive,Gemcitabine
16,Reactive Metabolite,Mechanisms of Liver Toxicity,0.0002731984912912581,Reactive Metabolite Formation,0.08638354328772263,False,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Positive,Gemcitabine
6,Animal hepatotoxicity B,Animal hepatotoxicity,-0.006212382672564701,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.29814192994294425,False,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Negative,Gemcitabine
7,Preclinical hepatotoxicity,Animal hepatotoxicity,-0.004995418646738177,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.7322230243527056,True,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Negative,Gemcitabine
14,BESP,Mechanisms of Liver Toxicity,-0.007950302998784051,BESP Bile Salt Export Pump Inhibition,0.003179599791282918,False,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Negative,Gemcitabine
15,Mitotox,Mechanisms of Liver Toxicity,-0.0009440625049571157,Mitotox ,0.05924541710869295,False,,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,Negative,Gemcitabine
2,Liver Toxicity Knowledge Base,DILI,0.020066710420176038,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.8635230438356896,True,,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,Positive,Minocycline
3,Human hepatotoxicity,Human hepatotoxicity,0.007986029784506599,"Human hepatotoxicity, hepatobiallry",0.8621640532169534,True,,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,Positive,Minocycline
8,Diverse DILI A,Heterogenous Data ,0.008182765417606987,Large-scale and diverse ddrug induced liver injury dataset,0.8483043475797644,True,,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,Positive,Minocycline
10,Diverse DILI B,Heterogenous Data ,0.01781662880554706,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.8766072718209441,True,,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,Positive,Minocycline
11,Diverse DILI C,Heterogenous Data ,0.004850145100762655,"Transient liver function abnormalities, adverse hepatic effects",0.7427958551326717,True,,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,Positive,Minocycline
15,Mitotox,Mechanisms of Liver Toxicity,0.0009838997248749004,Mitotox ,0.11497824179598226,False,,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,Positive,Minocycline
16,Reactive Metabolite,Mechanisms of Liver Toxicity,0.00032225663114200404,Reactive Metabolite Formation,0.14210135907589086,False,,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,Positive,Minocycline
5,Animal hepatotoxicity A,Animal hepatotoxicity,-0.0027250551981864764,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.06191490141076721,False,,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,Negative,Minocycline
6,Animal hepatotoxicity B,Animal hepatotoxicity,-0.0018491439160313859,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.13740895982229204,False,,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,Negative,Minocycline
7,Preclinical hepatotoxicity,Animal hepatotoxicity,-0.007658086069550882,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.72340879982954,True,,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,Negative,Minocycline
14,BESP,Mechanisms of Liver Toxicity,-0.0047010320187295535,BESP Bile Salt Export Pump Inhibition,0.03862642002670749,False,,CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,Negative,Minocycline
2,Liver Toxicity Knowledge Base,DILI,0.025642111327869973,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.8118688990225802,True,,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Positive,Moxifloxacin
3,Human hepatotoxicity,Human hepatotoxicity,0.010058580946585783,"Human hepatotoxicity, hepatobiallry",0.9296730238447772,True,,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Positive,Moxifloxacin
7,Preclinical hepatotoxicity,Animal hepatotoxicity,0.02876936490169001,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.8637990556114694,True,,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Positive,Moxifloxacin
8,Diverse DILI A,Heterogenous Data ,0.009306691699306806,Large-scale and diverse ddrug induced liver injury dataset,0.6633274168915236,True,,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Positive,Moxifloxacin
10,Diverse DILI B,Heterogenous Data ,0.016980930283586868,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.6412814085700572,True,,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Positive,Moxifloxacin
11,Diverse DILI C,Heterogenous Data ,0.008604861732091074,"Transient liver function abnormalities, adverse hepatic effects",0.7300803587123155,True,,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Positive,Moxifloxacin
16,Reactive Metabolite,Mechanisms of Liver Toxicity,0.00011859974838042376,Reactive Metabolite Formation,0.09994700360169603,False,,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Positive,Moxifloxacin
5,Animal hepatotoxicity A,Animal hepatotoxicity,-0.0024751044905035767,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.0709669682881259,False,,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Negative,Moxifloxacin
6,Animal hepatotoxicity B,Animal hepatotoxicity,-0.0021464322878506675,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.29859207552388295,False,,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Negative,Moxifloxacin
14,BESP,Mechanisms of Liver Toxicity,-0.0024221610536083117,BESP Bile Salt Export Pump Inhibition,0.10811137613490777,False,,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Negative,Moxifloxacin
15,Mitotox,Mechanisms of Liver Toxicity,-0.004560057066414292,Mitotox ,0.022381864431119537,False,,COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,Negative,Moxifloxacin
6,Animal hepatotoxicity B,Animal hepatotoxicity,4.675610459191401e-05,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.11568775207473282,False,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,Positive,Paclitaxel
8,Diverse DILI A,Heterogenous Data ,0.002643143961433851,Large-scale and diverse ddrug induced liver injury dataset,0.46075054974827473,False,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,Positive,Paclitaxel
10,Diverse DILI B,Heterogenous Data ,0.02472307238432903,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.7674177464150563,True,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,Positive,Paclitaxel
11,Diverse DILI C,Heterogenous Data ,0.0014843944495255216,"Transient liver function abnormalities, adverse hepatic effects",0.3809179265140355,False,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,Positive,Paclitaxel
14,BESP,Mechanisms of Liver Toxicity,0.0082896836125293,BESP Bile Salt Export Pump Inhibition,0.7995889015168934,True,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,Positive,Paclitaxel
15,Mitotox,Mechanisms of Liver Toxicity,0.011442157891340676,Mitotox ,0.4314559517487028,False,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,Positive,Paclitaxel
16,Reactive Metabolite,Mechanisms of Liver Toxicity,0.002330959443125489,Reactive Metabolite Formation,0.06447356077330317,False,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,Positive,Paclitaxel
2,Liver Toxicity Knowledge Base,DILI,-0.000842806781232693,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.575803445461335,True,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,Negative,Paclitaxel
3,Human hepatotoxicity,Human hepatotoxicity,-0.0004560327609901765,"Human hepatotoxicity, hepatobiallry",0.40075328614038297,False,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,Negative,Paclitaxel
5,Animal hepatotoxicity A,Animal hepatotoxicity,-0.0005423936568061009,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.14013889054133688,False,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,Negative,Paclitaxel
7,Preclinical hepatotoxicity,Animal hepatotoxicity,-0.0019996748219350035,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.7036934482541377,True,,CC(=O)O[C@H]1C(=O)[C@@]2(C)[C@H]([C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C1C3(C)C)[C@]1(OC(C)=O)CO[C@@H]1C[C@@H]2O,Negative,Paclitaxel
2,Liver Toxicity Knowledge Base,DILI,0.014333062484318659,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.8578598986211333,True,,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,Positive,Sitaxentan
3,Human hepatotoxicity,Human hepatotoxicity,0.007721544136963071,"Human hepatotoxicity, hepatobiallry",0.9106336905380022,True,,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,Positive,Sitaxentan
5,Animal hepatotoxicity A,Animal hepatotoxicity,0.0018357219699117807,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.5144292607057482,True,,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,Positive,Sitaxentan
6,Animal hepatotoxicity B,Animal hepatotoxicity,0.004016739985600628,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.584304415024456,True,,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,Positive,Sitaxentan
7,Preclinical hepatotoxicity,Animal hepatotoxicity,0.025344759022226826,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.8922453409790319,True,,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,Positive,Sitaxentan
8,Diverse DILI A,Heterogenous Data ,0.007018747889754225,Large-scale and diverse ddrug induced liver injury dataset,0.6906650296843283,True,,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,Positive,Sitaxentan
10,Diverse DILI B,Heterogenous Data ,0.01047683441538419,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.6611252339221857,True,,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,Positive,Sitaxentan
11,Diverse DILI C,Heterogenous Data ,0.006262691601018748,"Transient liver function abnormalities, adverse hepatic effects",0.6745730209998355,True,,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,Positive,Sitaxentan
14,BESP,Mechanisms of Liver Toxicity,0.003124886601026927,BESP Bile Salt Export Pump Inhibition,0.9451700872916944,True,,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,Positive,Sitaxentan
15,Mitotox,Mechanisms of Liver Toxicity,0.007202676618893947,Mitotox ,0.33710286677418333,False,,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,Positive,Sitaxentan
16,Reactive Metabolite,Mechanisms of Liver Toxicity,0.00039198907747011456,Reactive Metabolite Formation,0.20603328130200355,False,,Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,Positive,Sitaxentan
2,Liver Toxicity Knowledge Base,DILI,0.023017192411326066,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.8900497550262263,True,,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12,Positive,Trovafloxacin
3,Human hepatotoxicity,Human hepatotoxicity,0.00885681879912063,"Human hepatotoxicity, hepatobiallry",0.9706650051513318,True,,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12,Positive,Trovafloxacin
7,Preclinical hepatotoxicity,Animal hepatotoxicity,0.02688538859780553,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.8736970344782311,True,,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12,Positive,Trovafloxacin
8,Diverse DILI A,Heterogenous Data ,0.008888920375012233,Large-scale and diverse ddrug induced liver injury dataset,0.6437315005356323,True,,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12,Positive,Trovafloxacin
10,Diverse DILI B,Heterogenous Data ,0.016743686151993585,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.7813195995852361,True,,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12,Positive,Trovafloxacin
11,Diverse DILI C,Heterogenous Data ,0.008316620340837234,"Transient liver function abnormalities, adverse hepatic effects",0.7085940806605435,True,,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12,Positive,Trovafloxacin
15,Mitotox,Mechanisms of Liver Toxicity,0.004404771915921457,Mitotox ,0.14661000625278428,False,,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12,Positive,Trovafloxacin
5,Animal hepatotoxicity A,Animal hepatotoxicity,-0.0010144346344383263,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.09872129753475002,False,,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12,Negative,Trovafloxacin
6,Animal hepatotoxicity B,Animal hepatotoxicity,-0.0034191665608020285,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.3084375945242585,False,,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12,Negative,Trovafloxacin
14,BESP,Mechanisms of Liver Toxicity,-0.001421408986698912,BESP Bile Salt Export Pump Inhibition,0.2523629033190665,False,,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12,Negative,Trovafloxacin
16,Reactive Metabolite,Mechanisms of Liver Toxicity,-0.0011145020255631894,Reactive Metabolite Formation,0.2707154190219609,False,,N[C@@H]1[C@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@@H]12,Negative,Trovafloxacin
2,Liver Toxicity Knowledge Base,DILI,0.024622131885454885,"Liver Toxicity Knowledge Base (LTKB), prescription drugs, hepatotoxicity",0.7556773593919086,True,,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N/O)cc1)C1CCCCC1,Positive,Ximelagatran
3,Human hepatotoxicity,Human hepatotoxicity,0.009434253280312395,"Human hepatotoxicity, hepatobiallry",0.9019221794408125,True,,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N/O)cc1)C1CCCCC1,Positive,Ximelagatran
8,Diverse DILI A,Heterogenous Data ,0.01139971966027422,Large-scale and diverse ddrug induced liver injury dataset,0.6172066489799882,True,,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N/O)cc1)C1CCCCC1,Positive,Ximelagatran
10,Diverse DILI B,Heterogenous Data ,0.02577060626243349,"US drug-induced liver injury network (DILIN) , acute liver failure, withdrawn or suspended in US or European markets",0.7308475522258661,True,,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N/O)cc1)C1CCCCC1,Positive,Ximelagatran
14,BESP,Mechanisms of Liver Toxicity,0.0034054254145779,BESP Bile Salt Export Pump Inhibition,0.29873619560839737,False,,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N/O)cc1)C1CCCCC1,Positive,Ximelagatran
16,Reactive Metabolite,Mechanisms of Liver Toxicity,0.0019660586137335684,Reactive Metabolite Formation,0.053982443892406355,False,,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N/O)cc1)C1CCCCC1,Positive,Ximelagatran
5,Animal hepatotoxicity A,Animal hepatotoxicity,-0.000834474363588535,"Rat, chronic oral administration, Hepatic histopathologic effects, ToxRefDB",0.1180536550724014,False,,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N/O)cc1)C1CCCCC1,Negative,Ximelagatran
6,Animal hepatotoxicity B,Animal hepatotoxicity,-0.0028917146486051835,"Hepatocellular hypertrophy, rats, ORAD, HESS",0.17547281368993173,False,,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N/O)cc1)C1CCCCC1,Negative,Ximelagatran
7,Preclinical hepatotoxicity,Animal hepatotoxicity,-0.0024184456430295666,"Preclinical hepatotoxicity data from PharmaPendium, Leadscopre, and internal repository with 14- to 28-day rat study data",0.7032043367117646,True,,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N/O)cc1)C1CCCCC1,Negative,Ximelagatran
11,Diverse DILI C,Heterogenous Data ,-0.0011976455443566633,"Transient liver function abnormalities, adverse hepatic effects",0.4108782028015879,False,,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N/O)cc1)C1CCCCC1,Negative,Ximelagatran
15,Mitotox,Mechanisms of Liver Toxicity,-0.004898347220345659,Mitotox ,0.024464885196017232,False,,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(/C(N)=N/O)cc1)C1CCCCC1,Negative,Ximelagatran
